VF
KLRS

Virtu Financial’s Kalaris Therapeutics KLRS Stock Holding History

Virtu Financial’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,025
Closed -$20K – 2196
2024
Q4 		$20K Buy
+2,025
New +$30.6K ﹤0.01% 1305
2024
Q1 		– Sell
-1,794
Closed -$28K – 2231
2023
Q4 		$28K Buy
+1,794
New +$70.7K ﹤0.01% 1268
2023
Q3 		– Sell
-594
Closed -$46K – 2016
2023
Q2 		$46K Buy
+594
New +$56.5K ﹤0.01% 1152
2022
Q3 		– Sell
-614
Closed -$55K – 2330
2022
Q2 		$55K Buy
+614
New +$64.4K ﹤0.01% 1099

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial's KLRS Position: Q1 2025 in Review

Virtu Financial sold out of Kalaris Therapeutics (KLRS) in Q1 2025, closing a stake of 2,025 shares — an estimated $20K sold.

Virtu Financial first reported a position in KLRS in Q2 2022 and held it in 4 quarters. The position peaked at $55K in Q2 2022. 32 funds tracked by Wall St. Rank hold KLRS as of Q1 2025.

  • Virtu Financial reported no remaining Kalaris Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtu Financial sold 2,025 Kalaris Therapeutics shares in Q1 2025, an estimated $20K.
  • Virtu Financial first reported a position in Kalaris Therapeutics in Q2 2022 and held it in 4 quarters.
  • Virtu Financial's Kalaris Therapeutics position peaked at $55K in Q2 2022.
  • 32 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2025.

Based on Virtu Financial's 13F filing for Q1 2025, filed 12 May 2025.